






Increased prevalence of kidney cysts in individuals carrying heterozygous COL4A3 or COL4A4 pathogenic variants

Mónica Furlano ^{1,*}, Melissa Pilco-Teran ^{1,*}, Marc Pybus², Víctor Martínez³, Miriam Aza-Carmona², Asunción Rius Peris⁴, Vanessa Pérez-Gomez ⁵, Gerson Berná⁶, Jaime Mazon⁷, Jonathan Hernández⁸, Leonor Fayos de Arizón⁶, Elisabet Viera⁶, Ignasi Gich⁹, Hugo Vergara Pérez⁴, Elena Gomá-Garcés⁵, José Luis Albero Dolon³, Elisabet Ars ^{2,†} and Roser Torra ^{1,†}

¹Inherited Kidney Diseases, Nephrology Department, Fundació Puigvert, Institut de Recerca Sant Pau, Department of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

²Molecular Biology Laboratory, Fundació Puigvert, Institut de Recerca Sant Pau, Barcelona, Spain

³Nephrology Department, Hospital Universitario Virgen de la Arrixaca, Arrixaca, Spain

⁴Nephrology Department, Hospital General Universitario de Castellón, Castellón, Spain

⁵Nephrology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

⁶Nephrology Department, Fundació Puigvert, Barcelona, Spain

⁷Nephrology Department, Hospital de Valdecilla, Santander, Spain

⁸Radiology Department, Fundació Puigvert, Barcelona, Spain

⁹Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain

Correspondence to: Roser Torra; E-mail: rtorra@fundacio-puigvert.es, Elisabet Ars; E-mail: ears@fundacio-puigvert.es

*M.F. and M.P.-T. contributed equally to this work.

†E.A. and R.T. contributed equally to this work.

ABSTRACT

Background. Clinical variability among individuals with heterozygous pathogenic/likely pathogenic (P/LP) variants in the COL4A3/COL4A4 genes (also called autosomal dominant Alport syndrome or COL4A3/COL4A4-related disorder) is huge; many individuals are asymptomatic or show microhematuria, while others may develop proteinuria and chronic kidney disease (CKD). The prevalence of simple kidney cysts (KC) in the general population varies according to age, and patients with advanced CKD are prone to have them. A possible association between heterozygous COL4A3, COL4A4 and COL4A5 P/LP variants and KC has been described in small cohorts. The presence of KC in a multicenter cohort of individuals with heterozygous P/LP variants in the COL4A3/COL4A4 genes is assessed in this study.


Methods. We evaluated the presence of KC by ultrasound in 157 individuals with P/LP variants in COL4A3 (40.7%) or COL4A4 (53.5%) without kidney replacement therapy. The association between presence of KC and age, proteinuria, estimated glomerular filtration rate (eGFR) and causative gene was analyzed. Prevalence of KC was compared with historical case series in the general population.

Results. Half of the individuals with P/LP variants in COL4A3/COL4A4 showed KC, which is a significantly higher percentage than in the general population. Only 3.8% (6/157) had cystic nephromegaly. Age and eGFR showed an association with the presence of KC ($P < .001$). No association was found between KC and proteinuria, sex or causative gene.

Conclusions. Individuals with COL4A3/COL4A4 P/LP variants are prone to develop KC more frequently than the general population, and their presence is related to age and to eGFR. Neither proteinuria, sex nor the causative gene influences the presence of KC in these individuals.

Keywords: Alport syndrome, COL4A3, COL4A4, kidney cysts, type IV collagen nephropathy

GRAPHICAL ABSTRACT



KEY LEARNING POINTS

What was known:

- Insufficient information is available in the literature on the prevalence of kidney cysts (KC) in individuals with pathogenic/likely pathogenic (P/LP) variants in the COL4A3/COL4A4 genes.

This study adds:

- This is the largest cohort published to date of individuals with P/LP variants in the COL4A3/COL4A4 genes and ultrasound assessment to evaluate the presence of KC.
- It demonstrates that the presence of KC in these individuals is higher than in age-matched general population.
- The prevalence of KC is associated with age and estimated glomerular filtration rate.

Potential impact:

- This study demonstrates that there is an association between P/LP variants in the COL4A3/COL4A4 genes and presence of KC.
- There is currently insufficient evidence to recommend testing for COL4A3–COL4A5 variants in cystic kidney panels but it may be considered. The clinical impact of KC in these individuals seems to be negligible.

INTRODUCTION

Kidney cysts (KC) result from genetic and nongenetic processes and occur in multiple diseases as well as in healthy individuals. The most common type of radiologically evident KC in adults are simple cysts [1]. Simple KC are commonly observed in normal-sized kidneys, with an increasing incidence with age [2, 3]. Although the volume of the kidney is usually normal, these cysts can exceptionally increase the total kidney volume.

KC are benign, asymptomatic lesions that rarely require treatment [4–6]. The clinical concerns that usually arise regarding

KC are (i) whether malignancy can be ruled out and (ii) whether the KC can be considered simple cysts or part of a disease [7].

The prevalence of simple KC varies according to the studied series, for example from 0% to 10% in individuals younger than 20 years [8], from 5% to 20% in those aged between 20 and 50 years, and from 30% to 50% in those older than 60 years [1, 2, 9]. Bilateral KC are much less common and seem to be rare in subjects <50 years of age [1, 9–11]. It has also been reported that KC are more common in men than in women [1].

The most frequent inherited cystic kidney disease is autosomal dominant polycystic kidney disease (ADPKD) [12, 13]. It is characterized by multiple bilateral fluid-filled cysts, progressively increased kidney volume and irreversible renal insufficiency [13, 14]. However, KC also occur in other inherited kidney diseases, such as autosomal recessive polycystic kidney disease, autosomal dominant tubulointerstitial kidney disease, nephronophthisis, tuberous sclerosis complex, von Hippel-Lindau disease, hereditary angiopathy with nephropathy, aneurysms and muscle cramps (HANAC) syndrome, autosomal dominant liver disease, *HNF1B* nephropathy and oral-facial-digital syndrome [15].

Acquired cystic kidney disease (ACKD) is defined as the presence of three or more cysts in each kidney in patients with advanced cystic kidney disease (CKD) or on kidney replacement therapy (KRT), and small or normal-sized kidneys. It seems to be caused by prolonged uremia and may represent aberrant compensatory tubular growth as its prevalence increases as kidney function declines [16–19]. The reported prevalence of ACKD is as low as 7% in predialysis patients and as high as 80% in patients who have been on KRT for 10 years [17].

Pathogenic/likely pathogenic (P/LP) sequence variants in the *COL4A3*/*COL4A4* genes cause a condition that is under-recognized (ranging from completely normal urine sediment to microhematuria, proteinuria and renal insufficiency), poorly understood and not yet well classified [20–22]. Recently, the prevalence of heterozygous P/LP variants in *COL4A3*/*COL4A4* has been reported to be as high as 1 in 106 of the population [23]. Although we have previously published a cohort of patients with this condition and referred to them as having autosomal dominant Alport syndrome [24], this name is probably no longer appropriate, given the high prevalence in the population and the lack of extrarenal or even renal manifestations in most individuals. Also, from a medical-ethical point of view, it seems inappropriate to consider individuals without any clinical features as “patients.” Further insight into this entity is needed before an appropriate name can be given [25–28].

Small cohorts of individuals with collagen type IV nephropathy and KC have been reported [29, 30], which raises the possibility of a link between P/LP variants in these genes and KC.

Here we present the largest series published to date, which demonstrates an increased prevalence of KC in individuals with heterozygous P/LP variants in the *COL4A3*/*COL4A4* genes.

MATERIALS AND METHODS

A multicenter cohort, based in part on a previously reported cohort of patients with heterozygous P/LP variants in the *COL4A3*/*COL4A4* genes [24] and kidney ultrasound, was retrospectively studied (Supplementary data, Table S1). Individuals were referred for genetic testing in the context of families with autosomal dominantly inherited hematuria ± proteinuria and/or CKD, or index patients with an abnormal glomerular basement membrane. It consisted of a total of 157 adults (>18 years old) without KRT, belonging to 104 families from different Spanish hospitals [24].

The following clinical data were recorded at the time of kidney ultrasound: age, sex, serum creatinine, estimated glomerular filtration rate (eGFR; measured by CKD Epidemiology Collaboration), presence of hematuria, presence of lithiasis, and proteinuria measured by urinary protein/creatinine ratio and divided into four categories: no proteinuria, albuminuria (30–300 mg/gCr), non-nephrotic proteinuria (300–3500 mg/gCr) and nephrotic-range proteinuria (>3500 mg/gCr). Kidney length and number of KC in

each kidney were recorded. Nephromegaly was considered when the kidney size was >13 cm by ultrasound [31–33].

One plus (1+) KC were defined as the presence of at least one cyst in one kidney. Three plus (3+) KC were considered present when three or more KC were observed, either unilaterally or bilaterally.

Data from a published general population cohort that assessed the prevalence and size of KC using magnetic resonance imaging (MRI) was used to compare the presence of KC [3]. This cohort comprised 2063 participants in the Pomeranian Health Study conducted in a general German population sample between 2008 and 2012 [3].

This study was approved by the Fundació Puigvert institutional review board and the different healthcare provider institutional review boards. All participants signed their informed consent to participation in the study.

Genetic testing

Genetic testing had been performed by next generation sequencing of a kidney-disease gene panel containing *COL4A3*, *COL4A4* and *COL4A5* genes, along with other genes associated to inherited kidney diseases [24, 34, 35] (Supplementary data, Table S2) in 106 individuals. In all of them, 85 genes related to KC were thoroughly analyzed to discard any other genetic cause of KC. In the remaining 51 individuals, targeted familial variant analysis was performed by Sanger or multiplex ligation-dependent probe amplification analysis (MLPA). Variants were classified using American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines [36], and P or LP variants were considered causative. Segregation analysis was performed, in patients with available family members, by Sanger sequencing or MLPA. A digenic/complex inheritance pattern was considered present when two P/LP variants were identified in both *COL4A3*/*COL4A4* genes.

Statistical analysis

Categorical variables are expressed as percentages and frequencies and were compared using Pearson's chi-squared test. Quantitative variables with normal distribution are expressed by measures of central tendency, including mean and standard deviation, and were compared using Student's t-test. The logistic regression analysis was modelled with age and eGFR as dependent variables. The general population comparison analysis was performed using the two-proportions z-test. A P-value <.05 was considered statistically significant.

All statistical analyses were conducted in R (R version 4.1.2).

RESULTS

Baseline characteristics of the study cohort

The cohort included a total of 157 individuals from 104 families (56.6% women 89/157) with P/LP variants in the *COL4A3* (40.1%; 64/157) or *COL4A4* (54.1%; 86/157) gene (Table 1). Nine individuals showed a digenic inheritance (5.7%; 9/157). Hematuria was present in 92.3% (145/157) and albuminuria or proteinuria were present in 63.7% (100/157) of the patients. Only 12.1% (19/157) of the patients exhibited a severe eGFR category (G4 and G5). The mean age at the time of kidney ultrasound was 47.8 ± 13.6 years old and the mean eGFR was estimated at 73.0 ± 32.5 mL/min/1.73 m². Average right and left kidney lengths fell within the expected normal distribution (104.2 ± 13.1 and 105.3 ± 12.1 mm, respectively). Nephromegaly was observed in six patients, and three

Table 1: Baseline characteristics of the cohort.

Cohort study	N = 157 [n/N (%)]
Sex (female)	92/157 (58.6)
Hematuria	145/156 (92.9)
Causative gene	
COL4A3	64/157 (40.7)
COL4A4	84/157 (53.5)
Digenic (COL4A3 and COL4A4)	9/157 (5.7)
eGFR category	
G1	58/157 (36.9)
G2	38/157 (24.2)
G3a	19/157 (12.1)
G3b	23/157 (14.6)
G4	14/157 (8.9)
G5	5/157 (3.2)
Proteinuria/creatinine ratio	
No albuminuria (<30 mg/gCr)	57/157 (36.3)
Albuminuria (30–300 mg/gCr)	52/157 (33.12)
Non-nephrotic (300–3500 mg/gCr)	43/157 (27.3)
Nephrotic (>3500 mg/gCr)	5/157 (3.2)
Lithiasis	3/142 (2.1)
Presence of 1+ KC	
Either kidney	84/157 (53.5)
Bilateral	53/157 (33.7)
Presence of 3+ KC	
Either kidney	44/157 (28.0)
Bilateral	41/157 (26.1)

Cohort study	N = 157 (mean ± SD)
Kidney length	
Right kidney (mm)	104.2 ± 13.1
Left kidney (mm)	105.3 ± 12.1
Age (years)	47.8 ± 13.6
eGFR (mL/min/1.73 m ²)	73.0 ± 32.5

of them showed bilateral nephromegaly with 3+ KC (Table 2). The mean kidney lengths of the right and left kidneys of these patients with nephromegaly were 143.83 ± 16.31 and 134.17 ± 11.99 mm respectively. Only three patients showed lithiasis at ultrasound.

Association of KC and clinical variables

KC were present in 53.5% of the patients (84/157) and bilateral KC in 63% (53/84) of those. Besides, 28.0% (44/157) of the patients showed 3 or more KC in either kidney. The percentage of individuals by age and eGFR strata and the number of KC are shown in [Supplementary data, Table S3](#). In a univariate association analysis, only older age and lower eGFR were found to be statistically associated with the presence of 1+ KC ($P < .001$) (Table 3), as well

Table 2: Characteristics of patients with nephromegaly (kidney length >130 mm) and KC.

Patient	Sex	Age (years)	eGFR (mL/min/1.73 m ²)	CKD category	PCR (mg/gCr)	RKS (mm)	LKS (mm)	Number RKC	Number LKC
07–0440	M	37	101	1	207	132	132	0	0
12–508	M	51	38	3b	761	170	150	3+	3+
20–0003	F	38	56	3a	284	139	145	3+	3+
20–0517	M	46	105	1	15	133	125	1	1
21–0463	M	22	125	1	40	131	118	0	1
22–0640	M	65	54	3a	65	158	135	3+	3+

F: female; LKC: left kidney cysts; LKS: left kidney size; M: male; PCR: protein/creatinine ratio; RKC: right kidney cysts; RKS: right kidney size.

Table 3: Association analysis for presenting 1+ KC in either kidney.

	1+ KC	No KC	P-value
Sex (female)	55.9 (47/84)	61.6 (45/73)	.57
Hematuria	91.7 (77/84)	93.1 (67/72)	.98
Causative gene (COL4A3)	43.2 (35/81)	43.3 (29/67)	1
Lithiasis	2.8 (2/72)	1.4 (1/70)	1
Age (years)	53.3 ± 12.9	41.5 ± 11.6	<.001
eGFR (mL/min/1.73 m ²)	62.3 ± 31.2	85.3 ± 29.7	<.001
PCR (mg/gCr)	488.5 ± 946.6	509.0 ± 1069.4	.89

Data are presented as % (n/N) or mean ± SD.
PCR: protein/creatinine ratio.

Table 4: Association analysis for presenting 3+ KC in either kidney.

	3+ KC	<3 KC	P-value
Sex (female)	52.3 (23/44)	61.1 (69/113)	.41
Hematuria	93.2 (41/44)	91.9 (103/112)	1
Causative gene (COL4A3)	38.1 (16/42)	45.3 (48/106)	.54
Lithiasis	0.0 (0/37)	2.8 (3/105)	.71
Age (years)	56.3 ± 11.2	44.4 ± 13.1	<.001
eGFR (mL/min/1.73 m ²)	51.1 ± 29.2	81.5 ± 29.7	<.001
PCR (mg/gCr)	664.2 ± 1184.1	433.3 ± 919.8	.24

Data are presented as % (n/N) or mean ± SD.
PCR: protein/creatinine ratio.

Table 5: Logistic regression analysis for presenting 1+ KC or 3+ KC in either kidney.

	1+ KC (OR, P-value)	3+ KC (OR, P-value)
Age (years)	1.06, $P < .003$	1.05, $P < .008$
eGFR (mL/min/1.73 m ²)	0.99, $P = .09$	0.97, $P < .001$

OR: odds ratio.

as the presence of 3+ KC ($P < .001$) (Table 4). Both variables were then included in a multivariate logistic regression analysis that showed a statistically significant association of age with the presence of 1+ KC ($P = .003$), and of age and eGFR with the presence of 3+ KC ($P = .008$ and $P = .001$, respectively) (Table 5).

Causative gene and presence of KC

Among patients with P/LP variants in COL4A3, 54.7% (35/64) presented with KC while among patients with P/LP variants in COL4A4, 54.8% (46/84) presented with KC; there was no statistically significant association between gene and the presence of KC.

Table 6: Comparison of prevalence in presenting 1+ KC in either kidney by sex and age in this cohort study and a cohort from the general population.

Age (years)	20–29	30–39	40–49	50–59	60–69	>70	Total
Males							
This cohort study	1/4 (25)	4/10 (40)	8/17 (47)	11/17 (64.7)	8/10 (80)	4/4 (100)	36/62 (58.1)
General population ^a	13/92 (14.1)	29/146 (19.8)	62/239 (25.9)	84/236 (35.5)	86/177 (48.6)	67/121 (55.3)	341/1011 (33.7)
P-value	1	.267	.108	.030	.107	.277	<.001
Females							
This cohort study	2/7 (28.6)	7/23 (30.4)	9/20 (45)	15/25 (60)	11/13 (84.6)	4/4 (100)	48/92 (52.1)
General population ^a	5/70 (7.1)	17/151 (11.2)	40/263 (15.2)	50/267 (18.7)	71/209 (33.9)	40/92 (43.4)	223/1052 (21.2)
P-value	.233	.031	.002	.0001	.0007	.087	<.001

Data are presented as n/N (%).

^aFrom Mensel et al. [3] Three patients under 20 years were not included in this analysis (all without kidney cysts).

Comparison with a cohort from the general population

Data from Mensel et al. [3] were used to perform a sex- and age-matched general population comparison analysis of 1+ KC prevalence estimates found in this study cohort (Table 6). Males with COL4A3 or COL4A4 P/LP variants showed a prevalence of 58.1% (36/62) compared with 33.7% (341/1011) in the general population ($P < .0001$). Females showed a prevalence of 52.1% (48/92) compared with 21.2% (223/1052) in the general population ($P < .0001$). Additionally, an age-matched analysis showed higher prevalence across all age groups within each sex, but only reached a statistically significant association in the group age of 50- to 59-year-old males, and in the group age of 30- to 69-year-old females.

DISCUSSION

Some small cohort studies have reported the presence of KC in individuals with COL4A3/COL4A4 [30]. It has also been shown that KC coexist with focal segmental glomerulosclerosis, suggesting that KC can be caused by a severe defect in the glomerular basement membrane [37, 38]. In addition, KC have been described in a small cohort of 32 patients with kidney biopsy-proven thin basement membrane disease (TBMD) without genetic testing, showing a positive correlation with proteinuria; in contrast, no KC were detected in patients with TBMD with normal kidney function and without proteinuria [29]. It has been hypothesized that KC may result from distension of basement membranes weakened by disruption of the collagen type IV and that the cysts originate from the glomeruli or distal tubules because the collagen type IV $\alpha 3$, $\alpha 4$ and $\alpha 5$ chains are expressed only in these membranes [30, 37, 38].

The present study provides genetic, clinical and radiologic information of a cohort of 157 individuals from Spanish hospitals with heterozygous P/LP variants in COL4A3/COL4A4 genes.

In the general population, the incidence of KC seems to increase with age, and this also held true in the present cohort [1–3, 39–42]. However, the prevalence of KC in the present cohort was higher than that in the age-matched general population studied by Mensel et al. [3] even though Mensel's cohort was assessed by MRI, where a higher sensitivity is expected. This finding supports the hypothesis that these individuals have a greater predisposition to develop bilateral KC. In the general population KC are more common in males; this was also true in the present cohort, although it did not reach statistical significance.

It is also known that patients with CKD are more prone to have KC and this correlates with the decline in eGFR [9, 16, 40, 43]. In

the present cohort, worse eGFR was also associated with the presence of KC. However, even very mildly affected individuals showed an increased prevalence of KC. One study in healthy individuals in the general population found creatinine to be a risk factor for the development of KC, with serum creatinine 1.5 mg/dL (eGFR < 60 mL/min/1.73 m²) as a cut-off point [9]. However, we have not been able to identify studies evaluating the presence of KC for each CKD category, although it is well known that ACKD occurs in advanced CKD categories (G4 and G5) and individuals on KRT. Our study shows that the presence of KC increases along with eGFR decline in individuals with heterozygous P/LP variants in the COL4A3/COL4A4 genes. However, unlike what has been published in a smaller cohort [29], we do not observe an association with proteinuria in our cohort.

No genotype–phenotype association regarding presence of KC was identified in the present study. P/LP variants in other genes associated with ciliopathies that cause cystic kidney disease were ruled out, therefore collagen type IV variants are presumably the only genetic drivers of this feature. Cystic nephromegaly mimicking ADPKD has been reported in patients with COL4A3/COL4A4 variants [30] but in the present series only 3.8% of patients had nephromegaly. In view of this very low percentage of patients with P/LP variants in the COL4A3/COL4A4 genes with cystic nephromegaly, it seems advisable to exclude other inherited kidney diseases when cystic nephromegaly is present.

One limitation of our study is its inherent bias towards more severely affected individuals, which is a common characteristic of all clinical cohorts with P/LP variants in the COL4A3/COL4A4. This bias may be attributed to the underdiagnosis of individuals with a very mild or even nonexistent phenotype. Typically, individuals without kidney disease are not referred to nephrologists. However, the present cohort included individuals categorized as CKD-G1 and without proteinuria, most of them being relatives of the index case. Another limitation is the lack of evidence in the literature of the presence of KC in each CKD category, so we cannot make a direct comparison with other patients with CKD to determine whether this association is independent of eGFR.

In conclusion, we provide evidence that the prevalence of KC in individuals with P/LP variants in the COL4A3/COL4A4 genes is higher than in the general population and is associated with aging and worsening eGFR (advancing CKD category). However, it has no clinical consequences, and no cyst-specific treatment is required. Larger studies of clinical features in individuals with P/LP variants in the COL4A3/COL4A4 genes are needed to better understand this entity.

SUPPLEMENTARY DATA

Supplementary data are available at [Nephrology Dialysis Transplantation](#) online.

ACKNOWLEDGEMENTS

We acknowledge Ricard Pellejero from Fundació Puigvert for his bibliographic support. We thank IIB Sant Pau Biobank for providing some of the samples. Part of this work was presented at the annual meeting of the 51st (Virtual) Annual Congress of the Spanish Society of Nephrology 2021; Kidney Week 2022 Orlando, Florida and 60th European Renal Association Congress, Milan, Italy 2023.

FUNDING

This study was funded by the Instituto de Salud Carlos III (ISCIII)/Fondo Europeo de Desarrollo Regional (FEDER) funds (PI19/01633, PI22/00361, PT20/00196), the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) program to RICORS2040 (RD21/0005/0001) funded by European Union—NextGenerationEU, the Mechanism of recuperation and resilience (MRR), and FEDER funds; Fundació la Marató de TV3 202036-30. None of the funders had any role in study design, data collection, analysis, reporting or the decision to submit for publication.

AUTHORS' CONTRIBUTIONS

Research idea and study design: M.F., M.P.-T., E.A. and R.T.; data analysis/interpretation: M.F., M.P.-T., M.P., E.A. and R.T.; statistical analysis: M.P. and I.G.; cohort acquisition: M.F., M.P.-T., M.P., V.M., M.A.-C., A.R., V.P.-G., G.B., J.M., J.H., L.F., E.V., H.V.P., E.G.G., E.A. and R.T.; supervision or mentorship: E.A. and R.T. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate.

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

1. Simms RJ, Ong ACM. How simple are "simple renal cysts"? *Nephrol Dial Transplant* 2014;**29**:iv106–12. <https://doi.org/10.1093/ndt/gfu106>
2. Hommos MS, Glassock RJ, Rule AD. Structural and functional changes in human kidneys with healthy aging. *J Am Soc Nephrol* 2017;**28**:2838–44. <https://doi.org/10.1681/ASN.2017040421>
3. Mensel B, Kühn JP, Kracht F et al. Prevalence of renal cysts and association with risk factors in a general population: an MRI-based study. *Abdom Radiol (NY)* 2018;**43**:3068–74. <https://doi.org/10.1007/s00261-018-1565-5>
4. Chan J, Yan JH, Munir J et al. Comparison of Bosniak Classification of cystic renal masses version 2019 assessed by CT and MRI. *Abdom Radiol (NY)* 2021;**46**:5268–76. <https://doi.org/10.1007/s00261-021-03236-z>
5. Almalki YE, Basha MAA, Refaat R et al. Bosniak classification version 2019: a prospective comparison of CT and MRI. *Eur Radiol* 2023;**33**:1286–96. <https://doi.org/10.1007/S00330-022-09044-3/METRICS>
6. Schoots IG, Zaccai K, Hunink MG et al. Bosniak classification for complex renal cysts reevaluated: a systematic review. *J Urol* 2017;**198**:12–21. <https://doi.org/10.1016/J.JURO.2016.09.160>
7. Yang B, Qiu C, Wan S et al. Long-term follow-up study of the malignant transformation potential of the simple renal cysts. *Transl Androl Urol* 2020;**9**:684–9. <https://doi.org/10.21037/TAU.2020.03.29>
8. McHugh K, Stringer DA, Hebert D et al. Simple renal cysts in children: diagnosis and follow-up with US. *Radiology* 1991;**178**:383–5. <https://doi.org/10.1148/radiology.178.2.1987597>
9. Chang CC, Kuo JY, Chan WL et al. Prevalence and clinical characteristics of simple renal cyst. *J Chin Med Assoc* 2007;**70**:486–91. [https://doi.org/10.1016/S1726-4901\(08\)70046-7](https://doi.org/10.1016/S1726-4901(08)70046-7)
10. Ravine D, Gibson RN, Donlan J et al. An ultrasound renal cyst prevalence survey: specificity data for inherited renal cystic diseases. *Am J Kidney Dis* 1993;**22**:803–7. [https://doi.org/10.1016/S0272-6386\(12\)70338-4](https://doi.org/10.1016/S0272-6386(12)70338-4)
11. Eknayan G. A clinical view of simple and complex renal cysts. *J Am Soc Nephrol* 2009;**20**:1874–6. <https://doi.org/10.1681/ASN.2008040441>
12. Ars E, Bernis C, Fraga G et al. Consensus document on autosomal dominant polycystic kidney disease from the Spanish Working Group on Inherited Kidney Diseases. Review 2020. *Nefrologia* 2022;**42**:367–89. <https://doi.org/10.1016/J.NEFROE.2022.11.011>
13. Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. *Lancet North Am Ed* 2019;**393**:919–35. [https://doi.org/10.1016/S0140-6736\(18\)32782-X](https://doi.org/10.1016/S0140-6736(18)32782-X)
14. Willey CJ, Blais JD, Hall AK et al. Prevalence of autosomal dominant polycystic kidney disease in the European Union. *Nephrol Dial Transplant* 2017;**32**:1356–63. <https://doi.org/10.1093/ndt/gfw240>
15. Meola M, Samoni S, Petrucci I. Clinical scenarios in chronic kidney disease: cystic renal diseases. *Contrib Nephrol* 2016;**188**:120–30. <https://doi.org/10.1159/000445474>
16. Choyke PL. Acquired cystic kidney disease. *Eur Radiol* 2000;**10**:1716–21. <https://doi.org/10.1007/s003300000601>
17. Rahbari-Oskoui F, O'Neill WC. Diagnosis and management of acquired cystic kidney disease and renal tumors in ESRD patients. *Semin Dial* 2017;**30**:373–9. <https://doi.org/10.1111/SDI.12605>
18. Einollahi B. Are acquired cystic kidney disease and autosomal dominant polycystic kidney disease risk factors for renal cell carcinoma in kidney transplant patients? *J Nephrothol* 2012;**1**:65–8. <https://doi.org/10.5812/nephrothol.7447>
19. Neureiter D, Frank H, Kunzendorf U et al. Dialysis-associated acquired cystic kidney disease imitating autosomal dominant polycystic kidney disease in a patient receiving long-term peritoneal dialysis. *Nephrol Dial Transplant* 2002;**17**:500–3. <https://doi.org/10.1093/ndt/17.3.500>
20. Savige J, Huang M, Croos Dabrera MS et al. Genotype-phenotype correlations for pathogenic COL4A3–COL4A5 variants in X-linked, autosomal recessive, and autosomal dominant Alport syndrome. *Front Med (Lausanne)* 2022;**9**:1–8. <https://doi.org/10.3389/fmed.2022.865034>
21. Kashtan CE. Alport syndrome: achieving early diagnosis and treatment. *Am J Kidney Dis* 2021;**77**:272–9. <https://doi.org/10.1053/j.ajkd.2020.03.026>
22. Kashtan CE, Ding J, Garosi G et al. Alport syndrome: a unified classification of genetic disorders of collagen IV α 345: a position paper of the Alport Syndrome Classification Working Group.

- Kidney Int* 2018;**93**:1045–51. <https://doi.org/10.1016/j.kint.2017.12.018>
23. Gibson J, Fieldhouse R, Chan MMY et al. Prevalence estimates of predicted pathogenic col4a3-col4a5 variants in a population sequencing database and their implications for alport syndrome. *J Am Soc Nephrol* 2021;**32**:2273–90. <https://doi.org/10.1681/ASN.2020071065/-/DCSUPPLEMENTAL>
 24. Furlano M, Martínez V, Pybus M et al. Clinical and genetic features of autosomal dominant Alport syndrome: a cohort study. *Am J Kidney Dis* 2021;**78**:560–70.e1. <https://doi.org/10.1053/j.ajkd.2021.02.326>
 25. Savige J. Heterozygous pathogenic COL4A3 and COL4A4 variants (Autosomal Dominant Alport Syndrome) are common, and not typically associated with end-stage kidney failure, hearing loss, or ocular abnormalities. *Kidney Int Rep* 2022;**7**:1933–8. <https://doi.org/10.1016/j.ekir.2022.06.001>
 26. Daga S, Ding J, Deltas C et al. The 2019 and 2021 International Workshops on Alport syndrome. *Eur J Hum Genet* 2022;**30**:507–16. <https://doi.org/10.1038/s41431-022-01075-0>
 27. Savige J. Should we diagnose autosomal dominant alport syndrome when there is a pathogenic heterozygous COL4A3 or COL4A4 variant? *Kidney Int Rep* 2018;**3**:1239–41. <https://doi.org/10.1016/j.ekir.2018.08.002>
 28. Savige J, Lipska-Zietkiewicz BS, Watson E et al. Guidelines for genetic testing and management of Alport syndrome. *Clin J Am Soc Nephrol* 2022;**17**:143–54. <https://doi.org/10.2215/CJN.04230321>
 29. Sevillano AM, Gutierrez E, Morales E et al. Multiple kidney cysts in thin basement membrane disease with proteinuria and kidney function impairment. *Clin Kidney J* 2014;**7**:251–6. <https://doi.org/10.1093/ckj/sfu033>
 30. Gulati A, Sevillano AM, Praga M et al. Collagen IV gene mutations in adults with bilateral renal cysts and CKD. *Kidney Int Rep* 2020;**5**:103–8. <https://doi.org/10.1016/j.ekir.2019.09.004>
 31. Emamian SA, Nielsen MB, Pedersen JF et al. Kidney dimensions at sonography: correlation with age, sex, and habitus in 665 adult volunteers. *AJR Am J Roentgenol* 1993;**160**:83–6. <https://doi.org/10.2214/AJR.160.1.8416654>
 32. Cheong B, Muthupillai R, Rubin MF et al. Normal values for renal length and volume as measured by magnetic resonance imaging. *Clin J Am Soc Nephrol* 2007;**2**:38–45. <https://doi.org/10.2215/CJN.00930306>
 33. Braconnier P, Piskunowicz M, Vakilzadeh N et al. How reliable is renal ultrasound to measure renal length and volume in patients with chronic kidney disease compared with magnetic resonance imaging? *Acta Radiol* 2020;**61**:117–27. <https://doi.org/10.1177/0284185119847680>
 34. Bullich G, Domingo-Gallego A, Vargas I et al. A kidney-disease gene panel allows a comprehensive genetic diagnosis of cystic and glomerular inherited kidney diseases. *Kidney Int* 2018;**94**:363–71. <https://doi.org/10.1016/j.kint.2018.02.027>
 35. Domingo-Gallego A, Pybus M, Bullich G et al. Clinical utility of genetic testing in early-onset kidney disease: seven genes are the main players. *Nephrol Dial Transplant* 2021;**37**:687–96. <https://doi.org/10.1093/NDT/GFAB019>
 36. Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;**17**:405–24. <https://doi.org/10.1038/GIM.2015.30>
 37. Savige J, Harraka P. Pathogenic variants in the genes affected in Alport syndrome (COL4A3–COL4A5) and their association with other kidney conditions: a review. *Am J Kidney Dis* 2021;**78**:857–64. <https://doi.org/10.1053/j.ajkd.2021.04.017>
 38. Yoshioka K, Hino S, Takemura T et al. Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody. *Am J Pathol* 1994;**144**:986. <https://doi.org/pmc/articles/PMC1887361/?report=abstract>
 39. Chen J, Ma X, Xu D et al. Association between simple renal cyst and kidney damage in a Chinese cohort study. *Ren Fail* 2019;**41**:600–6. <https://doi.org/10.1080/0886022X.2019.1632718>
 40. Özveren B, Onganer E, Türkeri LN. Simple renal cysts: prevalence, associated risk factors and follow-up in a health screening cohort. *Urol J* 2016;**13**:2569–75.
 41. Terada N, Arai Y, Kinukawa N et al. Risk factors for renal cysts. *BJU Int* 2004;**93**:1300–2. <https://doi.org/10.1111/j.1464-410X.2004.04844.x>
 42. Carrim ZI, Murchison JT. The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. *Clin Radiol* 2003;**58**:626–9. [https://doi.org/10.1016/S0009-9260\(03\)00165-X](https://doi.org/10.1016/S0009-9260(03)00165-X)
 43. Chang A. Acquired cystic kidney disease. In: Nissenson A. R., Fine R. N (eds.), *Handbook of Dialysis Therapy: Fifth Edition*. United Kingdom: Elsevier, 2017, 721–4.e1. <https://doi.org/10.1016/B978-0-323-39154-2.00063-1>